Underused Heart Program May Cut Readmissions, Death Risk miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.
Australia: Daily administration of Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, for 14 days lowered Lipoprotein(a) levels up to 65% and was not associated with tolerability.
Successful early studies reported for two Lp(a)-lowering therapies healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in